Stevenage Bioscience Catalyst

Stevenage Bioscience Catalyst launches AI-powered drug discovery programme with Sentinal4D Fully funded pilot projects will give early-stage biotech companies access to Revvity’s advanced cellular imaging technology and Sentinal4D’s specialist AI analysis.

Stevenage, UK, 5 November 2026

Stevenage Bioscience Catalyst (SBC) has launched an AI-powered dru...

VasoDynamics receives Innovate UK Accelerate Knowledge Transfer Grant offer Collaboration with Bradford University to generate additional drug safety profiles for VasoDynamics’ topical formulations 30 October 2026

VasoDynamics Ltd, a pharmaceutical company developing patient-friendly, cost-effective therapies to prevent or reduce the debilita...

Santo Therapeutics Receives FDA IND Clearance for ST002 Gene Therapy for NF2-Related Schwannomatosis Milestone advances Santo’s in vivo tumour suppressor gene replacement programme into U.S. clinical development

HANGZHOU, China – October 30, 2026 – Santo Therapeutics Co., Ltd. (“Santo”), a biotechnology company developing nex...

NRG Therapeutics Announces a PET Biodistribution Trial of Lead Clinical Asset NRG5051

21 October 2026

Stevenage, UK, 21 October 2026 – NRG Therapeutics Ltd. (“NRG”), an innovative clinical stage neuroscience company targeting a novel mechanism to restore mitochondrial dysfunction in neurodegenerative diseases, today announced a positron emission tom...

Unravel Health, based at Stevenage Bioscience Catalyst, has announced a €2.96 million funding round to develop technology that could help women and clinicians better understand how changing hormone levels affect health.

The round is led by Conduit Connect and Henry Engelhardt, with participation from Leo Capital, Embryo Ventures and Hermesa, alongside follow-on investment fro...